DAIX, France--(BUSINESS WIRE)--Regulatory News:
Inventiva (Paris:IVA), a biopharmaceutical company developing innovative therapies, particularly to treat fibrosis, provided a business update and reported its interim financial results for the six months to June 30, 2017.
Business highlights
Lanifibranor (formerly IVA337)
- Lanifibranor granted as the international non-proprietary name (INN) for IVA337, the first next generation panPPAR a, d and ? to receive the fibranor suffix
- Positive results from the 12-month toxicity study of lanifibranor on primates: no adverse clinical signs were observed and none of the typical adverse effects related to PPAR? were observed
- Phase IIb NATIVE trial in NASH ongoing in Europe, Australia and Canada
- Data presented at 2017 International Liver Congress, the European Association for the Study of the Liver’s (EASL) annual conference, support the potential of lanifibranor as a treatment for NASH
- Enrollment on target in Phase IIb FASST study in patients with systemic sclerosis (SSc)
- Presentation of the latest results on lanifibranor at the 15th International Workshop on Scleroderma Research in the United States demonstrating its therapeutic potential in treating the vascular complications associated with SSc
Odiparcil (formerly IVA336)
- Phase IIa iMProveS study for patients with MPS VI, to begin enrollment before year end 2017
- Launch of the biomarkers study for odiparcil in the United States
- Award of orphan drug designation for odiparcil as a treatment for MPS VI in the United States and Europe
- New preclinical data on odiparcil presented at the MPS Society’s National Conference showing its efficacy in several organs where enzyme replacement therapies are not efficacious
- Strengthening of odiparcil intellectual property rights in the United States
Partnerships with AbbVie and Boehringer Ingelheim
